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S U M M A R Y
Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne disease caused by a
novel bunyavirus. Although the increasing numbers of cases and deaths is of great concern, an effective
treatment strategy for SFTS has not been established. We present the cases of two patients with rapidly
progressing SFTS who were successfully treated with plasma exchange and ribavirin.
 2013 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id
Open access under CC BY-NC-ND license.1. Introduction
Severe fever with thrombocytopenia syndrome (SFTS) was
ﬁrst identiﬁed in China in 2009. From 2011 to 2012, 2047 cases
were reported and 129 deaths occurred.1 Since the index case
was identiﬁed in Japan in January 2013, 17 additional cases
have been reported, and nine have died. In Korea, in May 2013,
the SFTS virus (SFTSV) was isolated from the stored blood
samples of a 64-year-old farmer who had died of a disease of
unknown etiology the previous year. As of the end of June
2013, 10 cases of SFTS have been reported and ﬁve deaths have
occurred.* Corresponding author. Tel.: +82 64 717 1296; fax: +82 64 717 1131.
E-mail address: neosangtaek@naver.com (S.T. Heo).
1201-9712       2013 The Authors. Published by Elsevier Ltd on behalf of International S
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2.1. Case 1
A 66-year-old farmer presented to a community hospital on Jeju
Island on May 28, 2013, with a 6-day history of fever and myalgia.
Because of a sudden drop in blood pressure, she was transferred to
a tertiary care hospital on Jeju Island on May 31.
On admission to the intensive care unit (ICU), she had a
temperature of 36.9 8C, blood pressure of 79/49 mmHg, an APACHE
II score of 27, and a Glasgow coma scale (GCS) score of 15
(Figure 1). Laboratory tests revealed a white blood cell (WBC)
count of 2.3  109/l, platelet count of 72  109/l, aspartate
aminotransferase (AST) level of 242 U/l, lactate dehydrogenase
(LDH) level of 900 U/l, and creatine phosphokinase (CPK) of 88 U/l.
She was treated with intravenous ﬂuids, norepinephrine, and
broad-spectrum antibiotics. She suddenly showed an altered
mental status on hospital day 3 (GCS score, 11). Ribavirin (4.0 g/
day) was administered orally after a positive SFTSV result from a
reverse transcriptase PCR (RT-PCR). On hospital day 4, plasma
exchange was performed using a COBE Spectra Apheresis System
(Terumo BCT, Lakewood, CO, USA). Based on her weight and
hematocrit, approximately 2200 ml of plasma was removed andociety for Infectious Diseases. Open access under CC BY-NC-ND license.
Figure 1. Clinical and laboratory ﬁndings of two patients with severe fever with thrombocytopenia syndrome (SFTS) before and after initiating plasma exchange and ribavirin.
Abbreviations: aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; CPK, creatine phosphokinase; GCS, Glasgow comma scale; HD, hospital day;
LDH, lactate dehydrogenase; MAP, mean arterial pressure; MV, mechanical ventilation; NE, norepinephrine; PLT, platelet; RBV, ribavirin; TPE, therapeutic plasma exchange;
WBC, white blood cell.
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donors each time (speed of blood output, 2333 ml/min; maximum
quantity of vitro blood circulation, 170 ml; interval of plasma
exchange, 24 h). The following night, her blood pressure began to
rise, even after discontinuing the norepinephrine infusion. Blood
pressure was maintained within the normal range, and the GCS score
increased to 13 on hospital day 6. Plasma exchange was
discontinued (frequency of plasma exchange, three times; total
volume of exchanged plasma, 6737 ml). She had recovered fully by
hospital day 9, with an APACHE II score of 5 and a GCS of 14.
2.2. Case 2
A 62-year-old farmer presented to a community hospital on Jeju
Island on June 5, 2013, with fever and altered mental status. He hada systolic blood pressure of 50 mmHg and was confused. He was
initially treated with intravenous ﬂuids, antibiotic agents, and
mechanical ventilation. On June 12, he was transferred to a tertiary
care hospital on Jeju Island immediately after a positive RT-PCR
result for SFTSV.
On admission to the ICU, he had a temperature of 37.3 8C, blood
pressure of 67/41 mmHg, an APACHE II score of 30, and a derived
GCS score of 3 (Figure 1). Laboratory tests revealed a WBC count of
9.5  109/l, platelet count of 75  109/l, AST of 184 U/l, LDH of 1481
U/l, and CPK of 588 U/l. Chest radiography showed bilateral diffuse
pulmonary inﬁltration, indicating pulmonary edema. He continued
to be mechanically ventilated with an FiO2 of 1.0. He was treated
with intravenous ﬂuids, norepinephrine, and broad-spectrum
antibiotics. Plasma exchange was performed using the same
method as described above. Based on his weight and hematocrit,
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fresh frozen plasma each time (speed of blood output, 4352 ml/
min; maximum quantity of vitro blood circulation, 170 ml;
interval of plasma exchange, 24 h). Oral ribavirin (4.0 g/day)
was administrated via a nasogastric tube. His derived GCS score
increased to 8, and blood pressure was maintained within the
normal range on hospital day 4, even after decreasing the infusion
rate of norepinephrine. Consequently, plasma exchange was
discontinued on hospital day 4 (frequency of plasma exchange,
four times; total volume of exchanged plasma, 14 141 ml).
Mechanical ventilation and norepinephrine were stopped on
hospital day 6. His condition improved to an APACHE II score of 12
and a GCS of 15 on hospital day 7.
3. Discussion
Of 10 conﬁrmed cases in Korea, four have been reported from
Jeju Island, southwest of the Korean Peninsula. All four patients
showed rapid progression to shock or multiple organ dysfunction
syndrome (MODS) and received supportive care in the ICU.
However, the ﬁrst two patients died of MODS and hemorrhage,
whereas the last two patients (cases 1 and 2), in whom plasma
exchange and ribavirin were initiated early, recovered from rapidly
progressing SFTS.
The cytokine-mediated inﬂammatory response may play an
important role in disease progression in patients with SFTS.2
Several cytokines (interleukin (IL)-1b, IL-8, macrophage inﬂam-
matory protein 1b, and interferon-gamma) are elevated in patients
with SFTS. Serum levels of these cytokines are correlated with
serum viral loads and disease severity. In addition, plasma
exchange has been shown to dramatically decrease serum cytokine
levels in patients with certain viral infections, together with
clinical improvement.3 This suggests that plasma exchange may
modulate the cytokine storm in SFTS patients, eventually resulting
in clinical improvement. In our cases, clinical and laboratory
parameters began to improve immediately after initiating plasma
exchange. Unfortunately, we did not measure serum cytokine
levels or viral loads in our cases before or after initiating plasma
exchange. Nevertheless, this clinical observation suggests that
plasma exchange leads to improvement in patients with SFTS with
shock or MODS that is refractory to intravenous ﬂuids and
vasopressors, probably by modulating the cytokine storm occur-
ring during an SFTSV infection.
Fatal outcomes in patients with SFTS have been found to be
correlated with a high blood viral load.2 In an animal study, SFTSV
adhered to mouse platelets and facilitated phagocytosis of
platelets by mouse macrophages.4 This suggests that SFTSV-
induced thrombocytopenia is caused by clearance of virus-bound
platelets by splenic macrophages, which is different from the
mechanism of thrombocytopenia seen in other bunyavirusinfections. Therefore, we speculate that ribavirin, combined with
plasma exchange, could reduce blood viral loads in patients with
SFTS to prevent SFTSV from binding to circulating platelets,
consequently avoiding phagocytosis by splenic macrophages.
This hypothesis may be supported, in part, by the ﬁnding that
platelet counts began to recover gradually after initiating
ribavirin in our cases.
Ribavirin has been known to be effective against several
bunyavirus infections, including Crimean-Congo hemorrhagic
fever, hemorrhagic fever with renal syndrome, hantavirus pulmo-
nary syndrome, and Rift Valley fever.5 In a recent study, 59 patients
with SFTS were treated with intravenous ribavirin (0.6 g/day).6
However, high-dose oral ribavirin (4.0 g/day), as recommended for
the treatment of Crimean-Congo hemorrhagic fever, was pre-
scribed to our patients because an intravenous formulation is not
available in Korea.
Our case report includes only two SFTS patients who were
treated with plasma exchange and ribavirin. In addition, we do not
know exactly how plasma exchange and ribavirin, or either, could
have had a favorable effect on the clinical and laboratory
parameters of our patients. Nevertheless, the clinical features
seen in our cases suggest that a combination of plasma exchange
and ribavirin can be used as a potential rescue therapy for patients
with SFTS who progress rapidly to shock or MODS even with
supportive care. Further studies on efﬁcacy and to determine the
mechanism of these therapeutic modalities in SFTS patients are
warranted.
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